New shot could tame tough eczema in phase 2 trial

NCT ID NCT07167758

Ongoing Disease control Sponsor: Triveni Bio Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests an experimental drug called TRIV-509 in 95 adults with moderate to severe atopic dermatitis (eczema). Participants receive four doses of either TRIV-509 or a placebo, then switch to the other group. The goal is to see if TRIV-509 improves eczema symptoms and is safe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

TRIV-509 (an experimental drug given as a shot under the skin)

What this could lead to

If successful, this could point toward a new treatment option for people with moderate to severe eczema that is not well controlled by current therapies.

What could go wrong

This is an early Phase 2a study with only 95 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being evaluated.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS

Contacts and locations

Show contact details

Locations

Triveni Bio Site #1

Camp Hill, Pennsylvania, 17011, United States
Triveni Bio Site #10

South Bend, Indiana, 46617, United States
Triveni Bio Site #11

Fountain Valley, California, 17271, United States
Triveni Bio Site #12

Niagara Falls, Ontario, L2H 1H5, Canada
Triveni Bio Site #13

Ajax, Ontario, L1S 7K8, Canada
Triveni Bio Site #15

North York, Ontario, M2N 3A6, Canada
Triveni Bio Site #16

Bellaire, Texas, 77401, United States
Triveni Bio Site #17

Newmarket, Ontario, L3Y 5G8, Canada
Triveni Bio Site #18

Kyiv, 01135, Ukraine
Triveni Bio Site #21

Prague, 11000, Czechia
Triveni Bio Site #22

Ostrava, 70200, Czechia
Triveni Bio Site #23

Prague, 15000, Czechia
Triveni Bio Site #24

Chorzów, Silesian Voivodeship, 41-500, Poland
Triveni Bio Site #25

Katowice, Silesian Voivodeship, 4-600, Poland
Triveni Bio Site #26

Poznan, Wielkopolska, 61-731, Poland
Triveni Bio Site #27

Katowice, Silesian Voivodeship, 40-611, Poland
Triveni Bio Site #28

Warsaw, Masovian Voivodeship, 00-872, Poland
Triveni Bio Site #29

Sosnowiec, 41-200, Poland
Triveni Bio Site #3

Miami, Florida, 33016, United States
Triveni Bio Site #30

Poznan, Wielkopolska, 60-309, Poland
Triveni Bio Site #31

Pardubice, 530 02, Czechia
Triveni Bio Site #33

Wroclaw, Lower Silesian Voivodeship, 51-604, Poland
Triveni Bio Site #34

Budapest, 1066, Hungary
Triveni Bio Site #37

Prague, 13000, Czechia
Triveni Bio Site #38

Pleven, 5800, Bulgaria
Triveni Bio Site #39

Sofia, 1172, Bulgaria
Triveni Bio Site #4

San Diego, California, 92123, United States
Triveni Bio Site #41

Budapest, 1033, Hungary
Triveni Bio Site #43

Debrecen, 4032, Hungary
Triveni Bio Site #5

Dallas, Texas, 75230, United States
Triveni Bio Site #6

Indianapolis, Indiana, 46250, United States
Triveni Bio Site #8

Spokane, Washington, 99202, United States